In situ carcinoma was significantly observed in 32% of patients with BRCA1/2 VUS with respect to the 11.2% of patients without BRCA1/2 variant (p = 0.005, Fisher Exact test). This evidence concerns the gene BRCA1 and in situ carcinoma.